Authors
Latest:
Dr Pant on the Background of the RAGNAR Trial in FGFR-altered Solid TumorsShubham Pant, MD, MBBS, discusses the background of the ongoing phase 2 RAGNAR trial evaluating the use of erdafitinib in patients with solid tumors harboring FGFR alterations.
Latest:
Tricks of the Trade: 4 Decades of WisdomMedical oncology can be a very demanding and taxing field.
Latest:
Dr Daneschmand on Data From SunRISe-1 With TAR-200 and Cetrelimab in BCG-Unresponsive NMIBCSia Daneshmand MD, discusses preliminary results from the phase 2 SunRISe-1 trial (NCT04640623) in patients with non–muscle invasive bladder cancer unresponsive to Bacillus Calmette-Guérin.
Latest:
Dr. Jabbari on the Potential for Implantable Cardiac Devices to Malfunction Following RTSiavash Jabbari, MD, discusses the potential for implantable cardiac devices to malfunction following radiation therapy.
Latest:
Dr. Blau on a Research-Based Approach to Meet OCM RequirementsSibel Blau, MD, medical oncology provider, medical director, Hematology/Oncology, Northwest Medical Specialties, discusses a value-based care model for oncology at the Association of Community Cancer Centers (ACCC) National Oncology Conference.
Latest:
Dr. Loibl Discusses GeparSepto Trial in Breast CancerSibylle Loibl, MD, PhD, co-chair of the German Breast Group (GBG) and associate professor at the University of Frankfurt, discusses the GeparSepto trial in subgroups of patients with breast cancer.
Latest:
Dr. Devarakonda on Biomarkers Beyond PD-L1 in NSCLCSiddhartha Devarakonda, MD, a senior fellow at Washington University School of Medicine in St. Louis, discusses biomarkers beyond PD-L1 being explored in patients with non–small cell lung cancer (NSCLC).
Latest:
A Closer Look at BRAF Melanoma Testing Reveals Intricacies of V600 MutationBRAF mutation testing has become an essential tool in the diagnostic workup and management of patients with advanced melanoma. Activating mutations of BRAF are present in 40% to 60% of all melanoma cases, with more than 90% of mutations found at codon 600 in exon 15.
Latest:
Talquetamab Dose Modifications May Lower AEs While Maintaining Efficacy in R/R Multiple MyelomaDose modifications of talquetamab improved on-target adverse effects while maintaining responses for patients with relapsed/refractory multiple myeloma.
Latest:
Dr. Formenti on Recent Progress With HER2-Targeted TherapySilvia Chiara Formenti, MD, chair, Department of Radiation Oncology, Weill Cornell, associate director, Meyer Cancer Center, radiation oncologist-in-chief, NewYork-Presbyterian Hospital, discusses the recent progress with HER2-targeted therapy in the treatment of breast cancer.
Latest:
Dr. Formenti on Combining Radiotherapy With Immunotherapy in NSCLCSilvia Formenti, MD, chair of Radiation Oncology at Weill Cornell Medical College and radiation oncologist-in-chief at Weill Cornell Medicine and NewYorkPresbyterian Hospital, discusses combining radiotherapy with immunotherapy in non-small cell lung cancer (NSCLC).
Latest:
Dr. Novello on the Gray Areas in Lung Cancer CareSilvia Novello, MD, PhD, assistant professor, Thoracic Oncology Unit, University of Turin, San Luigi Hospital, Orbassano, Italy, discusses some of the "gray areas" that require more research for the treatment of patients with lung cancer.
Latest:
Our Patients' Care Comes First, Even During Natural DisastersSimon Abi Aad, MD, discusses caring for patients during Hurricane Irma.
Latest:
Dr. Chowdhury on Separate Roles of Pazopanib and Pembrolizumab in RCCSimon Chowdhury, MA, MBBS, MRCP, PhD, consultant medical oncologist specializing in urological cancer, Sarah Cannon Research Institute, United Kingdom, discusses what roles pazopanib (Votrient) and pembrolizumab (Keytruda) have as monotherapy for patients with renal cell carcinoma (RCC).
Latest:
Dr. Chowdhury on Pembrolizumab Plus Pazopanib in RCCSimon Chowdhury, MD, consultant medical oncologist specializing in urological cancer, Sarah Cannon Research Institute, United Kingdom, discusses the combination of pembrolizumab (Keytruda) and pazopanib (Votrient) in patients with renal cell carcinoma (RCC).
Latest:
Dr. Chowdhury on Sequencing of Immunotherapy Regimens for RCCSimon Chowdhury, PhD, MA, MBBS, MRCP, consultant medical oncologist specializing in urological cancer, Sarah Cannon Research Institute, United Kingdom, discusses sequencing of immunotherapy regimens for patients with renal cell carcinoma (RCC).
Latest:
Dr. Harrison on Subcutaneous Daratumumab and Isatuximab in MyelomaSimon J. Harrison, MBBS, PhD, discusses the impact subcutaneous formulations of daratumumab and isatuximab could have in multiple myeloma.
Latest:
Dr. Rule on the Next Steps for BTK Inhibitors in MCLSimon Rule, MD, professor of hematology, University of Plymouth, discusses the next steps for ibrutinib (Imbruvica) and other BTK inhibitors in the treatment landscape of mantle cell lymphoma (MCL).
Latest:
Dr. Rule on the FDA Approval of Zanubrutinib in MCLSimon Rule, MD, PhD, professor of hematology, Plymouth University Medical School, United Kingdom, discusses the FDA approval of zanubrutinib (Brukinsa) in mantle cell lymphoma (MCL).
Latest:
Dr. Smita Bhatia on Anthracycline-Related CHFSmita Bhatia, MD, MPH, Population Sciences, City of Hope, Duarte, California, explains a clinical trial analyzing genetic susceptibility to anthracycline-related congestive heart failure in survivors of hematopoietic cell transplantation.
